Skip to content
HowShorted

REVIVA PHARMACEUTICALS HOLDINGS, INC. short interest in 2024

In 2024, REVIVA PHARMACEUTICALS HOLDINGS, INC.'s disclosed short interest ran from 3.23% of shares outstanding on 12 Jan 2024 to 16.88% on 31 Dec 2024, a change of +13.65 percentage points. The year's high was 26.31% on 13 Dec 2024 and its low 2.87% on 15 Mar 2024, averaging 11.99% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 32.43 days on 28 Jun 2024. Full history: REVIVA PHARMACEUTICALS HOLDINGS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for REVIVA PHARMACEUTICALS HOLDINGS, INC. in 2024

2024 in figures

Start of year
3.23% (12 Jan 2024)
End of year
16.88% (31 Dec 2024)
Change
+13.65 pp
High
26.31% (13 Dec 2024)
Low
2.87% (15 Mar 2024)
Average
11.99%
Highest days to cover
32.43 (28 Jun 2024)
SEC filings marked
8

Every report in 2024

REVIVA PHARMACEUTICALS HOLDINGS, INC. short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 20243.23%1.79
31 Jan 20243.71%2.97
15 Feb 20244.48%2.30
29 Feb 20243.79%4.25
15 Mar 20242.87%2.90
28 Mar 20244.67%2.06
15 Apr 20244.42%5.0610-K filed, results (8-K)
30 Apr 20244.48%11.79
15 May 20246.38%4.6410-Q filed, results (8-K)
31 May 202411.27%7.55
14 Jun 202411.03%12.93
28 Jun 202411.14%32.43
15 Jul 202412.98%16.77
31 Jul 202415.94%12.07
15 Aug 202414.89%13.5010-Q filed, results (8-K)
30 Aug 202418.30%4.75
13 Sep 202419.44%11.97
30 Sep 202418.34%17.50
15 Oct 202417.80%30.76
31 Oct 202417.77%14.58
15 Nov 202419.23%6.5910-Q filed, results (8-K)
29 Nov 202418.42%14.47
13 Dec 202426.31%1.76
31 Dec 202416.88%1.04

See also: REVIVA PHARMACEUTICALS HOLDINGS, INC.'s full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.